Evidence map›Paper›PMID 42131126›Full record

ArticleFrontiers in bioinformatics2026

Repurposing the angiotensin II receptor blocker valsartan to inhibit penicillin-binding protein 3 and its mutants in

Srujal Kacha, Janani Arun, Neelu Nargund, Tushar Joshi, Shalini Mathpal, Sudha Ramaiah, Anand Anbarasu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Srujal KachaMedical and Biological Computing Laboratory, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India.
Janani ArunDepartment of Biotechnology, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India.
Neelu NargundDepartment of Biotechnology, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India.
Tushar JoshiMedical and Biological Computing Laboratory, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India.
Shalini MathpalMedical and Biological Computing Laboratory, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India.
Sudha RamaiahMedical and Biological Computing Laboratory, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India.
Anand AnbarasuMedical and Biological Computing Laboratory, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Ampicillin-resistant Methods: In the current study, U.S. Food and Drug Administration (FDA)-approved drugs with structural similarity to ampicillin were filtered and evaluated using Results: An angiotensin II receptor blocker, valsartan, demonstrated strong binding affinity toward all three target proteins, with values of -11.8 kcal/mol for PBP3 Discussion: Based on these findings, valsartan is proposed as a potential PBP3 inhibitor targeting

Indexed as

drug repurposingHaemophilus influenzaemolecular dockingmolecular dynamic simulationpenicillin-binding protein 3valsartan

Identifiers

PMID42131126
PMCPMC13160910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.